Posted by Michael Wonder on 30 Aug 2017
More Canadians have access to Humira (adalimumab) for the treatment of ulcerative colitis
29 August 2017 - Humira (adalimumab) now reimbursed in British Columbia, Ontario, New Brunswick, Newfoundland and Labrador, Saskatchewan and Yukon.
AbbVie today announced that Humira (adalimumab) will now be reimbursed in British Columbia, Ontario, New Brunswick, Newfoundland and Labrador, Saskatchewan and Yukon for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy including corticosteroids, azathioprine and/or 6-mercaptopurine, or who are intolerant to such therapies.
It is also now covered by the federal Non-Insured Health Benefits program, which provides coverage to nearly one million status First Nations and Inuit peoples.
